Phillips-Medisize said today that it entered into an agreement with an unnamed biotechnology company to manufacture a wearable, electronic-enabled combination product for subcutaneous drug delivery.
The hockey puck-sized product is designed as a disposable, single-use combination device that can be worn near the infusion site for two days or adhere to the patient’s body with an adhesive patch. It is still under development.
Phillips-Medisize said it will provide the final assembly, testing and quality control for the product and will handle the pre-filled drug cartridge that fits inside the device. The product is expected to launch in the latter half of 2020, according to a news release.
The company said it is contracted to provide commercialization services from its Hudson, Wis. manufacturing site, pending FDA approval.
“This exciting new contract taps over 13 years of Phillips-Medisize’s combination product expertise, which includes cold chain drug handling and first programs with API handling,” Phillips-Medisize president & CEO Matt Jennings said in the news release. “We have experience in manufacturing both combination and electronic-enabled drug delivery devices, and this is our first product submitted for FDA approval that includes both.”
